Since systemic JAK inhibitors did not deplete MSA-specific CD8+ TRM in the vitiligo mouse model (52), the anti-CD122 Ab could be a more durable and safer treatment strategy for vitiligo. This evidence concerns the gene CD8A and vitiligo.